Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $638000.0.

  • Inhibrx Biosciences' Amortization of Deferred Charges changed N/A to $638000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 4574.28%. This contributed to the annual value of $2.1 million for FY2024, which is 5784.85% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Amortization of Deferred Charges stood at $638000.0 for Q3 2025.
  • In the past 5 years, Inhibrx Biosciences' Amortization of Deferred Charges registered a high of $1.2 million during Q4 2023, and its lowest value of $533000.0 during Q1 2025.
  • In the last 3 years, Inhibrx Biosciences' Amortization of Deferred Charges had a median value of $823000.0 in 2024 and averaged $906857.1.
  • The largest annual percentage gain for Inhibrx Biosciences' Amortization of Deferred Charges in the last 5 years was 2393.68% (2025), contrasted with its biggest fall of 5708.53% (2025).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Amortization of Deferred Charges stood at $1.2 million in 2023, then tumbled by 34.0% to $823000.0 in 2024, then dropped by 22.48% to $638000.0 in 2025.
  • Its Amortization of Deferred Charges was $638000.0 in Q3 2025, compared to $626000.0 in Q2 2025 and $533000.0 in Q1 2025.